CAJ | 학술논문

目的评价尖吻蝮蛇血凝酶对甲状腺切除患者的止血作用及安全性.方法采用前瞻、随机、盲法、对照研究设计,满足方案入选标准并获得知情同意的甲状腺疾病患者共60例,分为研究组(30例)于术前20 min静脉注射尖吻蝮蛇血凝酶2U,术后4h再次注射2U,对照组(30例)给予生理盐水;观察记录术中出血量和术后24 h创面引流量;同时观察凝血功能变化和安全性.结果研究组术中出血量(40.6±19.5)g与对照组(54.1 ±22.3)g相比减少(t=2.496,P=0.015);研究组术后24 h创面引流量(56.4±24.8)g少于对照组(73.0±31.5) g(t =2.268,P=0.027);凝血功能指标两组间差异无统计学意义.2组患者均未出现血栓等并发症.本研究中未出现研究药物相关的不良事件.结论尖吻蝮蛇血凝酶对甲状腺切除手术创面有较好的止血作用,并且未增加血栓形成的风险,有较好的安全性.
목적 평개첨문복사혈응매대갑상선절제환자적지혈작용급안전성.방법 채용전첨、수궤、맹법、대조연구설계,만족방안입선표준병획득지정동의적갑상선질병환자공60례,분위연구조(30례)우술전20 min정맥주사첨문복사혈응매2U,술후4h재차주사2U,대조조(30례)급여생리염수;관찰기록술중출혈량화술후24 h창면인류량;동시관찰응혈공능변화화안전성.결과 연구조술중출혈량(40.6±19.5)g여대조조(54.1 ±22.3)g상비감소(t=2.496,P=0.015);연구조술후24 h창면인류량(56.4±24.8)g소우대조조(73.0±31.5) g(t =2.268,P=0.027);응혈공능지표량조간차이무통계학의의.2조환자균미출현혈전등병발증.본연구중미출현연구약물상관적불량사건.결론 첨문복사혈응매대갑상선절제수술창면유교호적지혈작용,병차미증가혈전형성적풍험,유교호적안전성.
Objective To evaluate the hemostatic effects of hemocoagulase agkistrodon on patients undergoing thyroid operation and to analyze its influence on thrombosis and its safety.Methods It was a prospective,randomized,single-blind aud controlled study,in which 60 patients were enrolled.2 U hemocoagulase agkistrodon was injected 20 minutes before and 4 hours after operation in the study group,while normal saline was used in the control group.The volume of intraoperative bleeding and 24 hours drainage after operation was recorded.Results Intra-operative hemorrhage of the study group (40.6 ± 19.5) g was obviously lower than the control group (54.1 ±22.3) g(t =2.496,P =0.015).The volume of 24 hours drainage after operation was (56.4 ± 24.8) g in the study group and (73.0 ± 31.5) g in the control group(t=2.268,P =0.027).The hemoagglutination indices were similar in the two groups and no complications such as thrombus occurred in the study group.No adverse event occurred in this study.Conclusions Hemocoagulase agkistrodon has good hemostatic effects and safety for patients undergoing thyroid operation,without increasing the risk of thrombosis.